ArticleJournal of oncology2020
The Clinical Relevance of p16 and p53 Status in Patients with Squamous Cell Carcinoma of the Vulva.
Article in Journal of oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Vulvar Squamous Cell Carcinoma: Scientific Progress and Impacts to Pathology Practice.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2026Review
- Risk stratification of groin node metastases in vulvar cancer biopsies based on histology and immunohistochemical staining.Journal of gynecologic oncology · 2026Article
- Molecular Subtypes of Vulvar Squamous Cell Carcinoma: The Significance of HPV-Independent/p53 Wild Type.Cancers · 2024Review
- Vulvar squamous cell carcinoma: The role of p53 and p16 immunohistochemistry.Gynecologic oncology reports · 2024Article
- Lymphovascular invasion and p16 expression are independent prognostic factors in stage I vulvar squamous cell carcinoma.Virchows Archiv : an international journal of pathology · 2024Article
- Review effects of radiation treatment on HPV-related vulvar cancer: a meta-analysis and systematic review.Frontiers in oncology · 2024Review
- The Importance of p16 and p53 Immunohistochemical Staining in Diagnosing Vulvar Lichen Simplex Chronicus Mimicking Vulvar Intraepithelial Neoplasia with False-Positive Human Papillomavirus Type 66.International journal of women's health · 2024Article
- Article
- P53 in Penile Squamous Cell Carcinoma: A Pattern-Based Immunohistochemical Framework with Molecular Correlation.Cancers · 2023Article
- Management of Early-Stage Vulvar Cancer.Cancers · 2022Review
- Human Papillomavirus‒Positive and ‒Negative Vulvar Squamous Cell Carcinoma Are Biologically but Not Clinically Distinct.The Journal of investigative dermatology · 2022Article
- 2020 WHO Classification of Female Genital Tumors.Geburtshilfe und Frauenheilkunde · 2021Article
- p53 Immunohistochemical Patterns in HPV-Independent Squamous Cell Carcinomas of the Vulva and the Associated Skin Lesions: A Study of 779 Cases.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the prognostic significance of HPV status in vulvar squamous cell carcinomas (VSCC) and to determine whether preoperative determination of p16 or p53 status would have clinical relevance.
methodsPatients treated for VSCC at a tertiary hospital in Sydney, Australia, from 2002 to 2014, were retrospectively evaluated (
resultsHPV DNA was detected in 19%, p16 expression in 53%, and p53 expression in 37% of patients. Kaplan-Meier survival estimates indicated that p16/HPV-positive patients had superior five-year disease-free survival (76% versus 42%, resp.,
conclusionThe p16/HPV and p53 status of VSCC allows separation of patients into two distinct clinicopathological groups, although 10% of patients fall into a third group which is HPV, p16, and p53 negative. p16 status was not independently prognostic in multivariable analysis. Treatment decisions should continue to be based on clinical indicators rather than p16 or p53 status.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.